Syndax Pharmaceuticals Management

Management criteria checks 1/4

Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 2.25 years. total yearly compensation is $9.13M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth €1.08M. The average tenure of the management team and the board of directors is 1.9 years and 7.8 years respectively.

Key information

Michael Metzger

Chief executive officer

US$9.1m

Total compensation

CEO salary percentage	7.4%
CEO tenure	2.3yrs
CEO ownership	0.06%
Management average tenure	1.9yrs
Board average tenure	7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Metzger's remuneration changed compared to Syndax Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$9m	US$678k	-US$209m
Sep 30 2023	n/a	n/a	-US$176m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$153m
Dec 31 2022	US$4m	US$640k	-US$149m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$818k
Mar 31 2022	n/a	n/a	US$15m
Dec 31 2021	US$3m	US$594k	US$25m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$91m
Mar 31 2021	n/a	n/a	-US$86m
Dec 31 2020	US$2m	US$577k	-US$77m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$63m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$3m	US$540k	-US$56m
Sep 30 2019	n/a	n/a	-US$61m
Jun 30 2019	n/a	n/a	-US$65m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$506k	-US$74m
Sep 30 2018	n/a	n/a	-US$74m
Jun 30 2018	n/a	n/a	-US$72m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$1m	US$492k	-US$61m

Compensation vs Market: Michael's total compensation ($USD9.13M) is above average for companies of similar size in the German market ($USD1.61M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Metzger (52 yo)

2.3yrs

Tenure

US$9,127,419

Compensation

Mr. Michael A. Metzger, M.B.A. serves as Chief Executive Officer at Syndax Pharmaceuticals, Inc since February 03, 2022 and has been its Director since July 4, 2019. He served as Senior Vice President and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Metzger	CEO & Director	2.3yrs	US$9.13m	0.062% $ 1.1m
Neil Gallagher	President	1.1yrs	US$4.04m	0.015% $ 268.7k
Keith Goldan	CFO, Treasurer & Chief Accounting Officer	1.9yrs	US$2.83m	0.017% $ 302.5k
Luke Albrecht	Senior VP	7.8yrs	US$2.59m	0.051% $ 886.0k
Catherine Madigan	Chief Medical Officer	2.2yrs	US$2.81m	0.043% $ 740.0k
Peter Ordentlich	Co-Founder & Chief Scientific Officer	18.6yrs	no data	0.00031% $ 5.4k
Richard Heyman	Co-Founder	no data	no data	no data
Ronald Evans	Co-Founder	no data	no data	no data
Michael Downes	Co-Founder	no data	no data	no data
Sharon Klahre	Vice President of Investor Relations & Communications	1.9yrs	no data	no data
Kevin McManus	Chief People Officer	less than a year	no data	no data
Joseph Eder	Member of Scientific Advisory Board & Chief Medical Officer	1.4yrs	no data	no data

1.9yrs

Average Tenure

54yo

Average Age

Experienced Management: 1T3's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Metzger	CEO & Director	4.8yrs	US$9.13m	0.062% $ 1.1m
Ronald Evans	Co-Founder	7.8yrs	no data	no data
Joseph Eder	Member of Scientific Advisory Board & Chief Medical Officer	7.8yrs	no data	no data
Keith Katkin	Independent Director	7.2yrs	US$581.02k	0.038% $ 655.4k
Pierre Legault	Independent Director	7.3yrs	US$575.59k	0.038% $ 655.4k
Dennis Podlesak	Independent Chairman	15.4yrs	US$1.10m	0.017% $ 295.5k
George Sledge	Member of Scientific Advisory Board	7.1yrs	US$23.05k	no data
Jedd D. Wolchok	Member of Scientific Advisory Board	7.8yrs	no data	no data
Briggs W. Morrison	Director	8.8yrs	US$30.91k	0.021% $ 365.3k
Hope Rugo	Member of Scientific Advisory Board	7.8yrs	no data	no data
Samir Khleif	Member of Scientific Advisory Board	7.8yrs	no data	no data
Julie Brahmer	Member of Scientific Advisory Board	8.4yrs	no data	no data

7.8yrs

Average Tenure

63yo

Average Age

Experienced Board: 1T3's board of directors are considered experienced (7.8 years average tenure).

Syndax Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Recent updates

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Profitability

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Now 24% undervalued

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

New minor risk - Share price stability

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

First half 2022 earnings released

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021)

Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

First half 2021 earnings released: US$0.98 loss per share (vs US$0.97 loss in 1H 2020)

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.56 loss in 1Q 2020)

Independent Chairman recently bought €164k worth of stock

Full year 2020 earnings released: US$1.87 loss per share (vs US$1.84 loss in FY 2019)

Revenue beats expectations

Syndax Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

New 90-day high: €19.50

Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting

New 90-day high: €16.00

Third quarter 2020 earnings released: US$0.46 loss per share

Revenue misses expectations

Syndax Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day high: €15.30

New 90-day high: €14.50

First half earnings released

Syndax Pharmaceuticals, Inc. announced that it has received funding from Frazier Healthcare Partners

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure